Cause-Specific Mortality in Multiple Myeloma Pre- and Post-CAR-T cell Therapy Approval

Key Points

• Mortality rates for multiple myeloma significantly decreased after CAR-T cell therapy approval, indicating better patient outcomes.
• Survival analysis found a reduction in cause-specific mortality during the period following CAR-T adoption, showing a clear trend.
• Observational analysis of patient records from various health systems highlights the impact of newer treatment options.
• These findings may support future healthcare decisions and signify the potential of CAR-T therapies in improving survival.